（编辑 楚丽君） 证券日报网讯 12月25日，建发致新发布公告称，公司董事会于近日收到公司高级管理人员程芳女士递 交的书面辞职报告。程芳女士因个人原因辞去公司副总经理职务，辞职后将不再担任公司高级管理职 务，但仍在公司工作。 ...

Group 1 - The company Jianfa Zhixin announced the resignation of Ms. Cheng Fang from her position as Vice President due to personal reasons, although she will continue to work within the company [1] - For the first half of 2025, the revenue composition of Jianfa Zhixin is as follows: vascular interventional devices account for 54.88%, surgical instruments for 18.91%, in vitro diagnostic reagents (IVD) for 14.36%, medical equipment for 5.77%, and other medical devices for 4.69% [1] - As of the report date, Jianfa Zhixin has a market capitalization of 13.3 billion yuan [1]

证券代码：301584 证券简称：建发致新 公告编号：2025-017 上海建发致新医疗科技集团股份有限公司 截至本公告日，程芳女士未直接持有公司股份，但通过公司员工持股平台间接 持有公司股票640,000股；通过中信证券资管建发致新员工参与创业板战略配售2号 集合资产管理计划(以下简称"资管计划")参与公司IPO战略配售，持有资管计划 2.08%的份额。同时，程芳女士为公司2022年股票期权激励计划的激励对象，持有 公司股票期权700,000份（已获授但尚未行权）。辞职后，程芳女士所持公司股份 将继续遵守《中华人民共和国证券法》《深圳证券交易所创业板股票上市规则》《 深圳证券交易所上市公司自律监管指引第18号——股东及董事、高级管理人员减持 股份》等相关法律法规和规范性文件的规定，并将继续履行其在公司首次公开发行 1 股票并上市时作出的各项仍在履行期限内的承诺。 程芳女士在公司担任副总经理期间，恪尽职守、勤勉尽责，公司及公司董事会 对其在任职期间为公司发展作出的贡献表示衷心感谢！ 特此公告。 关于公司高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述 ...

Core Viewpoint - Jianfa Zhixin is a nationwide high-value medical device distributor, primarily engaged in direct sales and distribution of medical devices, providing centralized operation services for medical consumables (SPD) to end hospitals [1] Group 1: Company Overview - Jianfa Zhixin has established a nationwide distribution network, focusing on medical consumables and IVD diagnostic products, maintaining long-term stable partnerships with over 100 well-known domestic and international medical device manufacturers [1] - The company has accumulated rich operational service experience by deeply analyzing the pain points of traditional medical device distribution and exploring industry transformation directions [1] Group 2: Market Potential - The SPD management model for medical devices still has vast development space, with a penetration rate of approximately 15.29% in public hospitals across the country as of the end of 2023, indicating significant market growth potential [1] - According to the "2023 Health and Wellness Development Statistical Bulletin," there are approximately 11,772 public hospitals in the country, further supporting the potential for expansion in the SPD project [1] Group 3: Investment Rating - The company is covered for the first time with an "Overweight" rating, reflecting confidence in its innovative approach to solving industry development challenges [1]

Core Viewpoint - The company emphasizes that the centralized procurement policy for medical devices is beneficial for the long-term healthy development of the medical device industry in China, despite concerns about its impact on profitability and the need for diversification into new business areas [1]. Group 1: Industry Insights - The centralized procurement policy, which aims to save costs for the medical insurance fund and residents, has been in place since 2020, leading to a growth phase in the medical device industry [1]. - The company’s main products, high-value medical consumables, have undergone multiple rounds of centralized procurement, covering areas such as vascular intervention, surgical medical consumables, and IVD diagnostic products [1]. Group 2: Company Strategy - The company has strategically diversified its product offerings to mitigate revenue fluctuations from single products and has actively developed distribution for innovative medical devices [1]. - In response to the DRGS policy and the demand for lean management of hospital consumables, the company has also expanded into SPD management services [1]. - The management is focused on high-quality development and is strategically evaluating new business forms, digital technologies, and service areas for potential inclusion in the company's growth strategy [1].

Group 1 - The report gives the company an "Accumulate" rating for the first time [2][55] - The company is a national high-value medical device distributor, established in 2010, focusing on direct sales and distribution of medical devices, and providing centralized operation services for medical consumables (SPD) [5][11] - The SPD management model for medical devices has significant growth potential, with a current penetration rate of approximately 15.29% in public hospitals, indicating a vast market opportunity [5][47] Group 2 - The company has maintained stable revenue and net profit growth from 2020 to 2024, with revenue increasing from 8.542 billion to 17.923 billion yuan, and net profit rising from 160 million to 228 million yuan [24][26] - The medical device market in China is expanding steadily, with the market size growing from 370 billion yuan in 2016 to 1,032.8 billion yuan in 2023, reflecting a compound annual growth rate (CAGR) of 15.79% [31][39] - The high-value medical consumables market in China has also shown steady growth, with a market size increase from 72.4 billion yuan in 2016 to 156.1 billion yuan in 2023, achieving a CAGR of 11.60% [39][40] Group 3 - The company leverages innovation to address industry challenges, focusing on technology, service, and management model improvements to enhance operational efficiency [48][49] - The company has developed a comprehensive SPD management system that integrates logistics information technology to optimize the management of medical consumables within hospitals [52] - The company aims to create a "national integrated medical device distribution hub," enhancing collaboration with major manufacturers and hospitals to streamline operations and improve service efficiency [53][54] Group 4 - The investment forecast estimates earnings per share of 0.66 yuan and 0.76 yuan for 2025 and 2026, respectively, with corresponding valuations of 48 times and 42 times [55][56] - The company is positioned to benefit from the ongoing trends of industry consolidation and increased efficiency in medical device distribution [44][45]

Group 1 - The core viewpoint of the news is that Jianfa Zhixin has shown fluctuations in its stock performance and financing activities, with a slight increase in stock price and notable changes in financing and shareholder metrics [1][2]. Group 2 - On December 22, Jianfa Zhixin's stock price increased by 0.09%, with a trading volume of 153 million yuan. The financing data indicates a financing buy-in of 11.06 million yuan and a financing repayment of 12.49 million yuan, resulting in a net financing outflow of 1.42 million yuan [1]. - As of December 22, the total balance of margin trading for Jianfa Zhixin is 123 million yuan, which accounts for 7.53% of its market capitalization [1]. - The company has not engaged in any short selling activities on December 22, with no shares sold or repaid [1]. Group 3 - As of November 30, the number of shareholders for Jianfa Zhixin is 30,200, a decrease of 20.40% from the previous period. The average circulating shares per person increased by 25.63% to 1,667 shares [2]. - For the period from January to September 2025, Jianfa Zhixin reported a revenue of 14.861 billion yuan, representing a year-on-year growth of 10.18%. The net profit attributable to the parent company was 230 million yuan, showing a significant increase of 45.01% year-on-year [2].

Group 1 - The core viewpoint of the article is that Jianfa Zhixin (301584) expects a positive growth in its medical surgical robot distribution business for the fiscal year 2025, with revenue showing a good increase compared to 2024 [1] Group 2 - The company responded to investor inquiries on an interactive platform, indicating that its business operations are proceeding normally [1] - The anticipated revenue growth for 2025 is highlighted as a significant aspect of the company's future performance [1]

（文章来源：证券日报） 证券日报网讯 12月16日，建发致新在互动平台回答投资者提问时表示，公司主营医疗器械流通业务， 业务活动为医疗器械分销业务、直销业务和服务业务（医院SPD管理服务为主），2024年三项主要业务 活动的毛利率分别为7.91%、6.86%和39.80%，2024年整体毛利率为7.54%。2025年上半年度公司整体毛 利率为7.93%。公司的业务毛利率反映了行业属性，整体毛利率的发展趋势将受各项业务活动的毛利率 变动和业务活动结构的综合影响。 ...

公司已于近日完成了上述事项所涉及的工商变更登记及《上海建发致新医疗 科技集团股份有限公司章程》备案手续，并取得了上海市市场监督管理局换发的 《营业执照》。现将具体情况公告如下： 一、变更后的营业执照基本情况 1、名称：上海建发致新医疗科技集团股份有限公司 2、统一社会信用代码：91310104560199492F 证券代码：301584 证券简称：建发致新 公告编号：2025-016 上海建发致新医疗科技集团股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海建发致新医疗科技集团股份有限公司（以下简称"公司"）于2025年10 月24日召开第三届董事会第十次会议和第三届监事会第九次会议，于2025年11月 12日召开2025年第二次临时股东大会，审议通过了《关于变更公司注册资本、公 司类型及修订<公司章程>并办理工商变更登记的议案》，具体内容详见公司于 2025年10月28日在巨潮资讯网（www.cninfo.com.cn）披露的《关于变更公司注册 资本、公司类型、修订<公司章程>及修订和新增公司部分治理 ...